What's new? Log in Free sign up

Praxis Precision Medicines (PRAX)

Company Profile

Company profile

Ticker

PRAX

Exchange

Website

www.praxismedicines.com

CEO

Mr. Marcio Silva De'Souza M.B.A.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

AIT Therapeutics, Inc., KokiCare, Inc.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

PRAX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$169.00

Low target

$163.00

High target

$175.00

Truist Securities

Oppenheimer

Maintains

Outperform

$163.00

31 Oct 24

Latest filings (excl ownership)

View all

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Automatic shelf registration

Quarterly report

6 Nov 24

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Departure of Directors or Certain Officers

Regulation FD Disclosure

Quarterly report

13 Aug 24

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Registration of securities for employees (post-effective amendment)

Departure of Directors or Certain Officers

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Lauren Mastrocola

Timothy Edwin Kelly

Lauren Mastrocola

Timothy Edwin Kelly

Lauren Mastrocola

Timothy Edwin Kelly

Financial summary

Financial statements Chart PRAX financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	169.06 mm	169.06 mm	169.06 mm	169.06 mm	169.06 mm	169.06 mm
Cash burn (monthly)	(no burn)	(no burn)	18.95 mm	13.67 mm	9.17 mm	8.29 mm
Cash used (since last report)	n/a	n/a	76.20 mm	54.97 mm	36.87 mm	33.35 mm
Cash remaining	n/a	n/a	92.86 mm	114.09 mm	132.19 mm	135.71 mm
Runway (months of cash)	n/a	n/a	4.9	8.3	14.4	16.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

PRAX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	138	120	+15.0%
Opened positions	34	43	-20.9%
Closed positions	16	33	-51.5%
Increased positions	45	40	+12.5%
Reduced positions	43	24	+79.2%

13F shares	Current	Prev Q	Change
Total value	1.02 tn	722.31 bn	+41.6%
Total shares	31.67 mm	30.29 mm	+4.5%
Total puts	309.50 k	501.93 k	-38.3%
Total calls	364.30 k	540.40 k	-32.6%
Total put/call ratio	0.8	0.9	-8.5%

Largest owners	Shares	Value	Change
Cormorant Global Healthcare Master Fund	9.50 mm	$10.45 mm	0.0%
Vida Ventures	1.47 mm	$0.00	0.0%
BlackRock	1.30 mm	$74.94 bn	NEW
Perceptive Advisors	1.16 mm	$66.98 bn	+55.2%
T. Rowe Price	1.12 mm	$64.45 mm	+19.3%
Vanguard	1.04 mm	$59.78 bn	+6.3%
Point72 Asset Management	1.03 mm	$59.45 bn	-1.8%
Capital Research Global Investors	997.09 k	$57.37 bn	NEW
Venrock Healthcare Capital Partners III	906.49 k	$63.48 mm	+10.1%
Cormorant Asset Management	870.00 k	$50.06 bn	+27.0%

Largest transactions	Shares	Bought/sold	Change
BlackRock	1.30 mm	+1.30 mm	NEW
BLK BlackRock	0.00	-1.29 mm	EXIT
Capital Research Global Investors	997.09 k	+997.09 k	NEW
Adage Capital Management	854.08 k	+854.08 k	NEW
Ra Capital Management	761.96 k	-473.64 k	-38.3%
Vestal Point Capital	0.00	-440.00 k	EXIT
Perceptive Advisors	1.16 mm	+413.81 k	+55.2%
Deep Track Capital	0.00	-389.55 k	EXIT
Adage Capital Partners GP, L.L.C.	854.08 k	-280.00 k	-24.7%
Soleus Capital Management	259.40 k	-273.62 k	-51.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PRAX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
12 Jan 25	Timothy Edwin Kelly	Common Stock	Payment of exercise	Dispose F	No	No	63.15	676	42.69 k	24,030
12 Jan 25	Alex Nemiroff	Common Stock	Payment of exercise	Dispose F	No	No	63.15	579	36.56 k	20,882.667
12 Jan 25	Lauren Mastrocola	Common Stock	Payment of exercise	Dispose F	No	No	63.15	390	24.63 k	10,481.656
10 Jan 25	Marcio Souza	Common Stock	Grant	Acquire A	No	No	0	37,500	0.00	53,960
10 Jan 25	Marcio Souza	Stock Option Common Stock	Grant	Acquire A	No	No	63.15	75,000	4.74 mm	75,000
10 Jan 25	Timothy Edwin Kelly	Common Stock	Grant	Acquire A	No	No	0	12,500	0.00	24,706
10 Jan 25	Timothy Edwin Kelly	Stock Option Common Stock	Grant	Acquire A	No	No	63.15	25,000	1.58 mm	25,000
10 Jan 25	Alex Nemiroff	Common Stock	Grant	Acquire A	No	No	0	11,250	0.00	21,461.667
10 Jan 25	Alex Nemiroff	Stock Option Common Stock	Grant	Acquire A	No	No	63.15	22,500	1.42 mm	22,500
10 Jan 25	Lauren Mastrocola	Common Stock	Grant	Acquire A	No	No	0	5,000	0.00	10,871.656

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Expert Outlook: Praxis Precision Medicine Through The Eyes Of 5 Analysts

Truist Securities Maintains Buy on Praxis Precision Medicine, Raises Price Target to $175

Truist Securities analyst Joon Lee maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $150 to $175.

10 Health Care Stocks With Whale Alerts In Today's Session

Reported Earlier, Praxis Announces 2025 Milestones: Advancing Relutrigine, Ulixacaltamide, And Rare Disease Programs With $470M In Cash Reserves

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted For Relutrigine In Dravet Syndrome; Praxis Plans To Initiate An All-DEE Trial (EMERALD), Inclusive Of Dravet Syndrome, In 1H2025

Press releases

From Benzinga Pro

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028 Study 1 of Essential3 program for ulixacaltamide in essential tremor

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those granted for SCN2A

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.